Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Aged
Aged, 80 and over
Antigens, Surface
/ blood
CA-125 Antigen
/ blood
Case-Control Studies
Dendritic Cells
/ drug effects
Female
Flow Cytometry
Humans
Immunophenotyping
Lectins, C-Type
/ analysis
Male
Membrane Proteins
/ blood
Middle Aged
Ovarian Neoplasms
/ blood
Phenotype
Poly I-C
/ pharmacology
Prognosis
Prostatic Neoplasms
/ blood
Receptors, Mitogen
/ analysis
Thrombomodulin
Toll-Like Receptor 3
/ agonists
CD141
Cross-presenting DC
Ovarian cancer
Prostate cancer
Vaccines
cDC1
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
20
03
2020
accepted:
16
04
2020
pubmed:
27
6
2020
medline:
31
12
2020
entrez:
27
6
2020
Statut:
ppublish
Résumé
Dendritic cells (DCs) are the most efficient antigen-presenting cells, hence initiating a potent and cancer-specific immune response. This ability (mainly using monocyte-derived DCs) has been exploited in vaccination strategies for decades with limited clinical efficacy. Another alternative would be the use of conventional DCs (cDCs) of which at least three subsets circulate in human blood: cDC1s (CD141 Whole blood samples from patients with OvC or PrC and healthy donors (HDs) were evaluated by flow cytometry for the phenotypic and functional characterisation of DC subsets. In both patient groups, the frequency of total CD141 cDC1s are reduced in patients with OvC, and CD141
Sections du résumé
BACKGROUND
Dendritic cells (DCs) are the most efficient antigen-presenting cells, hence initiating a potent and cancer-specific immune response. This ability (mainly using monocyte-derived DCs) has been exploited in vaccination strategies for decades with limited clinical efficacy. Another alternative would be the use of conventional DCs (cDCs) of which at least three subsets circulate in human blood: cDC1s (CD141
PATIENTS AND METHODS
Whole blood samples from patients with OvC or PrC and healthy donors (HDs) were evaluated by flow cytometry for the phenotypic and functional characterisation of DC subsets.
RESULTS
In both patient groups, the frequency of total CD141
CONCLUSIONS
cDC1s are reduced in patients with OvC, and CD141
Identifiants
pubmed: 32590296
pii: S0959-8049(20)30240-9
doi: 10.1016/j.ejca.2020.04.036
pii:
doi:
Substances chimiques
Antigens, Surface
0
CA-125 Antigen
0
CLEC9a protein, human
0
Lectins, C-Type
0
MUC16 protein, human
0
Membrane Proteins
0
Receptors, Mitogen
0
THBD protein, human
0
TLR3 protein, human
0
Thrombomodulin
0
Toll-Like Receptor 3
0
Poly I-C
O84C90HH2L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-182Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement None declared.